rs137852696
Variant summary
Our verdict is Pathogenic. Variant got 13 ACMG points: 13P and 0B. PM1PM2PP3PP5_Very_Strong
The NM_000310.4(PPT1):c.223A>C(p.Thr75Pro) variant causes a missense change. The variant allele was found at a frequency of 0.0000628 in 1,608,864 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. T75T) has been classified as Likely benign.
Frequency
Consequence
NM_000310.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PPT1 | NM_000310.4 | c.223A>C | p.Thr75Pro | missense_variant | 2/9 | ENST00000642050.2 | |
PPT1 | NM_001363695.2 | c.223A>C | p.Thr75Pro | missense_variant | 2/8 | ||
PPT1 | NM_001142604.2 | c.125-2897A>C | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PPT1 | ENST00000642050.2 | c.223A>C | p.Thr75Pro | missense_variant | 2/9 | NM_000310.4 | P1 |
Frequencies
GnomAD3 genomes ? AF: 0.0000526 AC: 8AN: 152136Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 251446Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135896
GnomAD4 exome AF: 0.0000638 AC: 93AN: 1456728Hom.: 0 Cov.: 32 AF XY: 0.0000538 AC XY: 39AN XY: 725080
GnomAD4 genome ? AF: 0.0000526 AC: 8AN: 152136Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74316
ClinVar
Submissions by phenotype
Neuronal ceroid lipofuscinosis 1 Pathogenic:8
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 09, 2022 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jul 15, 1998 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 16, 2018 | Variant summary: PPT1 c.223A>C (p.Thr75Pro) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 246324 control chromosomes (gnomAD).The variant, c.223A>C, has been reported in the literature in multiple individuals affected with Neuronal Ceroid-Lipofuscinosis (Batten Disease), including at least one homozygote (Mitchison_1998). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function. The most pronounced variant effect results in <10% of normal activity. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | May 17, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Invitae | Jan 22, 2024 | This sequence change replaces threonine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 75 of the PPT1 protein (p.Thr75Pro). This variant is present in population databases (rs137852696, gnomAD 0.007%). This missense change has been observed in individual(s) with neuronal ceroid lipofuscinosis 1 (PMID: 9425237, 26510000, 28559085). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 8900). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt PPT1 protein function with a positive predictive value of 80%. Experimental studies are conflicting or provide insufficient evidence to determine the effect of this variant on PPT1 function (PMID: 23539563). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Dec 09, 2019 | NM_000310.3(PPT1):c.223A>C(T75P) is classified as pathogenic in the context of PPT1-related neuronal ceroid lipofuscinosis and is associated with the juvenile form of this disease. Sources cited for classification include the following: PMID 9425237, 9664077 and 23539563. Classification of NM_000310.3(PPT1):c.223A>C(T75P) is based on the following criteria: This is a well-established pathogenic variant in the literature that has been observed more frequently in patients with clinical diagnoses than in healthy populations. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Sep 20, 2023 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 08, 2021 | Published functional studies demonstrate the variant results in reduced PPT1 enzyme activity (Miller et al., 2013); Not observed at significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 14997939, 10649502, 26510000, 11520175, 19793631, 16720047, 22778232, 23542453, 11073228, 10781062, 16759889, 9664077, 20346914, 23857568, 29655203, 28559085, 23539563, 9425237) - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 07, 2021 | DNA sequence analysis of the PPT1 gene demonstrated a sequence change, c.223A>C, in exon 2 that results in an amino acid change, p.Thr75Pro. This sequence change has been described in the gnomAD database with a low frequency of 0.006% in African/African American subpopulation (dbSNP rs137852696). This sequence change has previously been described in the homozygous and compound heterozygous states in individuals and families with PPT1-related disorders (PMIDs: 9425237, 26510000). The p.Thr75Pro change affects a poorly conserved amino acid residue of the PPT1 protein. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Thr75Pro substitution. Functional studies suggest p.Thr75Pro reduces PPT1 enzyme activity (PMID: 23539563). Collectively these evidences suggest this p.Thr75Pro variant is pathogenic. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 09, 2022 | The c.223A>C (p.T75P) alteration is located in exon 2 (coding exon 2) of the PPT1 gene. This alteration results from a A to C substitution at nucleotide position 223, causing the threonine (T) at amino acid position 75 to be replaced by a proline (P). Based on data from gnomAD, the C allele has an overall frequency of <0.01% (4/251446) total alleles studied. The highest observed frequency was 0.01% (1/16256) of African alleles. This mutation has been identified in multiple individuals in the compound heterozygous and homozygous state (Miller, 2013; Mitchison, 1998; Metelitsina, 2016; Das, 1998; Stone, 2017; Jilani, 2019). This amino acid position is not well conserved in available vertebrate species. This alteration has been shown to reduce PPT1 enzyme activity (Miller, 2013). The in silico prediction for this alteration is inconclusive. Based on the available evidence, this alteration is classified as pathogenic. - |
PPT1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 23, 2023 | The PPT1 c.223A>C variant is predicted to result in the amino acid substitution p.Thr75Pro. This variant has been documented in the homozygous and compound heterozygous states as causative for neuronal ceroid lipofuscinosis 1 (CLN1) in several affected patients (Mitchison et al.1998. PubMed ID: 9425237; Das et al. 1998. PubMed ID: 9664077). This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/1-40558081-T-G). This variant is interpreted as pathogenic. - |
Retinitis pigmentosa Pathogenic:1
Pathogenic, criteria provided, single submitter | curation | Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard | Apr 01, 2021 | The p.Thr75Pro variant in PPT1 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: PM2, PP3, PM3-S, PS3. Based on this evidence we have classified this variant as Pathogenic. If you have any questions about the classification please reach out to the Pierce Lab. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at